Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

[1]  R. Vasan,et al.  Novel markers for heart failure diagnosis and prognosis , 2005, Current opinion in cardiology.

[2]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[3]  A. Dobson,et al.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.

[4]  M. Dolgin.  Obesity and B-type natriuretic peptide levels in heart failure. , 2005, Journal of the American College of Cardiology.

[5]  D. Mele,et al.  Tumor Necrosis Factor- (cid:1) Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction The Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study , 2005 .

[6]  Gabriel A. Rabinovich,et al.  Galectins as modulators of tumour progression , 2005, Nature Reviews Cancer.

[7]  W. Mori,et al.  Simulation of a 50GeV PWFA Stage , 2004 .

[8]  A. Matsumori,et al.  Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with heart failure. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[9]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[10]  A. Barbagelata,et al.  Ongoing Myocardial Injury in Stable Severe Heart Failure: Value of Cardiac Troponin T Monitoring for High-Risk Patient Identification , 2004, Circulation.

[11]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[12]  Albert Hofman,et al.  Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. , 2004, European heart journal.

[13]  A. Fukamizu,et al.  Regulatory Roles for APJ, a Seven-transmembrane Receptor Related to Angiotensin-type 1 Receptor in Blood Pressure in Vivo* , 2004, Journal of Biological Chemistry.

[14]  Susanne Carlsson,et al.  Introduction to galectins , 1997, Glycoconjugate Journal.

[15]  H. Naruse,et al.  Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. , 2003, Clinical chemistry.

[16]  Euan A Ashley,et al.  Novel Role for the Potent Endogenous Inotrope Apelin in Human Cardiac Dysfunction , 2003, Circulation.

[17]  F. Horkay,et al.  Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. , 2003, Biochemical and biophysical research communications.

[18]  J. McMurray,et al.  The rise and fall of myotrophin in heart failure. , 2003, Journal of the American College of Cardiology.

[19]  M. Jessup.  Aldosterone blockade and heart failure. , 2003, The New England journal of medicine.

[20]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[21]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[22]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[23]  Douglas N W Cooper,et al.  Galectinomics: finding themes in complexity. , 2002, Biochimica et biophysica acta.

[24]  J. Rysä,et al.  Apelin, the Novel Endogenous Ligand of the Orphan Receptor APJ, Regulates Cardiac Contractility , 2002, Circulation research.

[25]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[26]  Vera Bittner,et al.  Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. , 2002, Heart & lung : the journal of critical care.

[27]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[28]  H. Naruse,et al.  Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. , 2002, The American journal of cardiology.

[29]  H. Krumholz,et al.  β-Blocker Therapy in Heart Failure: Scientific Review , 2002 .

[30]  K. Weber.  Cardioreparation in Hypertensive Heart Disease , 2001, Hypertension.

[31]  P. Armstrong,et al.  A systematic review of randomized trials of disease management programs in heart failure. , 2001, The American journal of medicine.

[32]  J. Pell,et al.  Evidence of Improving Prognosis in Heart Failure: Trends in Case Fatality in 66 547 Patients Hospitalized Between 1986 and 1995 , 2000, Circulation.

[33]  O. Nishimura,et al.  Molecular and Functional Characteristics of APJ , 2000, The Journal of Biological Chemistry.

[34]  N. Tinari,et al.  Concentrations of galectin-3 in the sera of normal controls and cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  J. Cleland,et al.  Is the prognosis of heart failure improving? , 1999, Journal of the American College of Cardiology.

[36]  J. Cleland,et al.  Is the prognosis of heart failure improving? , 2000, European journal of heart failure.

[37]  R. Hughes.  Secretion of the galectin family of mammalian carbohydrate-binding proteins. , 1999, Biochimica et biophysica acta.

[38]  S. Hinuma,et al.  Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. , 1998, Biochemical and biophysical research communications.

[39]  M. Monsigny,et al.  Galectin-3 expression in human atherosclerotic lesions. , 1998, The American journal of pathology.

[40]  J. Kjekshus,et al.  Elevated circulating levels of C-C chemokines in patients with congestive heart failure. , 1998, Circulation.

[41]  B. Bruneau,et al.  BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. , 1997, The American journal of physiology.

[42]  J. Schaper,et al.  Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. , 1997, European heart journal.

[43]  T. LeJemtel,et al.  Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. , 1996, Journal of the American College of Cardiology.

[44]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[45]  D. Mann,et al.  Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.